|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer incidence and mortality
worldwide. IARC CancerBase no. 11, Lyon. 2013.
|
|
2
|
Pestana C, Reitemeier RJ, Moertel CG, Judd
ES and Dockerty MB: The natural history of carcinoma of the colon
and rectum. Am J Surg. 108:826–829. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Falterman KW, Hill CB, Markey JC, Fox JW
and Cohn I Jr: Cancer of the colon, rectum, and anus: A review of
2313 cases. Cancer. 34 Suppl:S951–S959. 1974. View Article : Google Scholar
|
|
4
|
Olson RM, Perencevich NP, Malcolm AW,
Chaffey JT and Wilson RE: Patterns of recurrence following curative
resection of adenocarcinoma of the colon and rectum. Cancer.
45:2969–2974. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moertel CG, Fleming TR, Macdonald JS,
Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA,
Tormey DC, Glick JH, et al: Levamisole and fluorouracil for
adjuvant therapy of resected colon carcinoma. N Engl J Med.
322:352–358. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ha GS, Kim YW, Choi EH and Kim IY: Factors
associated with the lack of adjuvant chemotherapy following
curative surgery for stage II and III colon cancer: A Korean
National Cohort Study. Anticancer Res. 37:915–922. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bos AC, van Erning FN, van Gestel YR,
Creemers GJ, Punt CJ, van Oijen MG and Lemmens VE: Timing of
adjuvant chemotherapy and its relation to survival among patients
with stage III colon cancer. Eur J Cancer. 51:2553–2561. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
No authors listed: Efficacy of adjuvant
fluorouracil and folinic acid in colon cancer. International
Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT)
investigators. Lancet. 345:939–944. 1995.PubMed/NCBI
|
|
9
|
Moertel CG, Fleming TR, Macdonald JS,
Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey
DC, Glick JH, et al: Fluorouracil plus levamisole as effective
adjuvant therapy after resection of stage III colon carcinoma: A
final report. Ann Intern Med. 122:321–326. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Connell MJ, Laurie JA, Kahn M,
Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI,
Pazdur R, Wieand HS, et al: Prospectively randomized trial of
postoperative adjuvant chemotherapy in patients with high-risk
colon cancer. J Clin Oncol. 16:295–300. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolmark N, Rockette H, Fisher B, Wickerham
DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ,
et al: The benefit of leucovorin-modulated fluorouracil as
postoperative adjuvant therapy for primary colon cancer: Results
from National Surgical Adjuvant Breast and Bowel Project protocol
C-03. J Clin Oncol. 11:1879–1887. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
NIH consensus conference. Adjuvant therapy
for patients with colon and rectal cancer. JAMA. 264:1444–1450.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peters GJ, Van der Wilt CL, van Groeningen
CJ, Smid K, Meijer S and Pinedo HM: Thymidylate synthase inhibition
after administration of fluorouracil with or without leucovorin in
colon cancer patients: Implications for treatment with
fluorouracil. J Clin Oncol. 12:2035–2042. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kelsen DP, Saltz L, Cohen AM, Yao TJ,
Enker W, Tong W, Tao Y and Bertino JR: A phase I trial of immediate
postoperative intraperitoneal floxuridine and leucovorin plus
systemic 5-fluorouracil and levamisole after resection of high risk
colon cancer. Cancer. 74:2224–2233. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Department of Health, the Executive Yuan,
. Cancer registry annual report. Taiwan, Republic of China:
2012
|
|
16
|
International Union Against Cancer, . TNM
classification of malignant tumors. Sobin LH and Wittekind C: 6th.
Wiley-Liss Inc; New York: 2002
|
|
17
|
Fleshman JW, Nelson H, Peters WR, Kim HC,
Larach S, Boorse RR, Ambroze W, Leggett P, Bleday R, Stryker S, et
al: Early results of laparoscopic surgery for colorectal cancer.
Retrospective analysis of 372 patients treated by Clinical Outcomes
of Surgical Therapy (COST) study group. Dis Colon Rectum. 39 10
Suppl:S53–S58. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franklin ME Jr, Rosenthal D, Abrego-Medina
D, Dorman JP, Glass JL, Norem R and Diaz A: Prospective comparison
of open vs. laparoscopic colon surgery for carcinoma. Five-year
results. Dis Colon Rectum. 39 10 Suppl:S35–S46. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bokey EL, Moore JW, Chapuis PH and Newland
RC: Morbidity and mortality following laparoscopic-assisted right
hemicolectomy for cancer. Dis Colon Rectum. 39 10 Suppl:S24–S28.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schwenk W, Bohm B and Müller JM:
Postoperative pain and fatigue after laparoscopic or conventional
colorectal resections. A prospective randomized trial. Surg Endosc.
12:1131–1136. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haller DG, Catalano PJ, Macdonald JS,
O'Rourke MA, Frontiera MS, Jackson DV and Mayer RJ: Phase III study
of fluorouracil, leucovorin, and levamisole in high-risk stage II
and III colon cancer: Final report of Intergroup 0089. J Clin
Oncol. 23:8671–8678. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Panettiere FJ, Goodman PJ, Costanzi JJ,
Cruz AB Jr, Vaitkevicius VK, McCracken JD, Brownlee RW, Laufman L,
Stephens RL, Bonnet J, et al: Adjuvant therapy in large bowel
adenocarcinoma: Long-term results of a Southwest Oncology Group
Study. J Clin Oncol. 6:947–954. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andre T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
André T, Boni C, Navarro M, Tabernero J,
Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F
and de Gramont A: Improved overall survival with oxaliplatin,
fluorouracil, and leucovorin as adjuvant treatment in stage II or
III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kurihara M, Uchida J, Fujioka A, Kato T,
Ohshimo H, Abe M, Takeda S and Fukushima M: Effect of combination
therapy with UFT plus cisplatin (UFTP) on the survival of mice in
the experimental model for wide-spread metastasis in the peritoneal
cavity of gastrointestinal cancer using colon 26 PMF-15 cells.
Anticancer Res. 17:2217–2220. 1997.PubMed/NCBI
|
|
28
|
Smith RE, Lembersky BC, Wieand HS,
Colangelo L and Mamounas EP: UFT/leucovorin vs 5-FU/leucovorin in
colon cancer. Oncology (Williston Park). 14 10 Suppl 9:S24–S27.
2000.
|
|
29
|
Pazdur R, Lassere Y, Rhodes V, Ajani JA,
Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL,
Bready B, et al: Phase II trial of uracil and tegafur plus oral
leucovorin: An effective oral regimen in the treatment of
metastatic colorectal carcinoma. J Clin Oncol. 12:2296–2300. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saltz LB, Leichman CG, Young CW, Muggia
FM, Conti JA, Spiess T, Jeffers S and Leichman LP: A fixed-ratio
combination of uracil and Ftorafur (UFT) with low dose leucovorin.
An active oral regimen for advanced colorectal cancer. Cancer.
75:782–785. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meropol NJ, Rustum YM, Petrelli NJ,
Rodriguez-Bigas M, Frank C, Ho DH, Kurowski M and Creaven PJ: A
phase I and pharmacokinetic study of oral uracil, ftorafur, and
leucovorin in patients with advanced cancer. Cancer Chemother
Pharmacol. 37:581–586. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mukai M, Moriya H, Himeno S, Oida Y,
mukohyama S, Nishi T, Nakasaki H, Satoh S and Makuuchi H: Efficacy
of oral UFT plus leucovorin therapy for colon cancer with ovarian
and multiple liver metastases: Report of two cases. Oncol Rep.
8:1079–1083. 2001.PubMed/NCBI
|
|
33
|
West HJ and Jin JO: JAMA oncology patient
page. Performance status in patients with cancer. JAMA Oncol.
1:9982015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
U.S. Department of Health and Human
Services, National Institutes of Health, National Cancer Institute.
Common terminology criteria for adverse events (CTCAE), version
4.0. 2009.
|
